Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. University of Pittsburgh, Pittsburgh, PA, United States



Survival: 16.4 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Pittsburgh, PA
   
Hospital: University of Pittsburgh
   
Journal: Link
   
Date: 11/2011

Description:
Patients:
This phase II study involved women with previously treated but recurrent or metastatic breast cancer who were divided into two separate treatment groups. Group A included 225 patients with a median age of 55 years. Group B consisted of 459 patients with a median age of 55 years.

Treatment:
Group A was treated with a chemotherapy regimen that included capecitabine, gemcitabine, vinorelbine, or a taxane-based agent in addition to a placebo.

Group B was treated with a chemotherapy regimen with one of the agents listed above as well as the biologic therapy agent bevacizumab, which is an antibody that blocks a protein involved in cancer cell growth.

Toxicities:
Five treatment-related deaths were reported for group A. The most common grade 3 or higher toxicities were neutropenia (14.5% of patients), sensory neuropathy (5.9%), and neutropenia with fever (2.7%).

For group B, six treatment-related deaths were reported. The most common grade 3 or higher toxicities were neutropenia (17.7% of patients), hypertension (9.0%), and sensory neuropathy (6.3%).

Results:
The median overall survival rates for groups A and B were 16.4 and 18.0 months, respectively.

Support:
This study was supported by Genentech, makers of Avastin (trade name for bevacizumab).

Correspondence: Dr. Adam Brufsky; email: brufskyam@upmc.edu

E-mail to a Friend Email Physician More Information